Technical Analysis for CBIO - Catalyst Inc.

Grade Last Price % Change Price Change
grade F 5.38 -4.10% -0.23
CBIO closed down 4.1 percent on Friday, October 18, 2019, on 1.31 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical CBIO trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.10%
Up 3 Days in a Row Strength -4.10%
Up 4 Days in a Row Strength -4.10%
Crossed Above 20 DMA Bullish -1.47%
Up 3 Days in a Row Strength -1.47%
20 DMA Resistance Bearish 0.94%
NR7 Range Contraction 0.94%
NR7-2 Range Contraction 0.94%
NR7 Range Contraction 1.70%

Older signals for CBIO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Catalyst Biosciences, Inc., a biopharmaceutical company, focuses on discovering and developing novel biopharmaceutical products based on engineered human proteases. The company designs its proteases to promote hemostasis and to prevent inflammation. Its pipeline of protease therapeutics include CB 813d/PF-05280602, an engineered Factor VIIa drug candidate that completed a Phase 1 clinical trial evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity. The company's pre-clinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of hemophilia B inhibitor patients; and an engineered Factor Xa for hemophilia and the control of bleeding in non-hemophilia patients. It also develops factor C3 for the prevention of renal delayed graft function and the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.
Biopharmaceutical Inflammation Molecular Biology Cell Biology Anatomy Pharmacokinetics Macular Degeneration Hemophilia Treatment Of Hemophilia Coagulation System Biopharmaceutical Products Coagulation Pharmacodynamics Dry Age Related Macular Degeneration Factor X
Is CBIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.445
52 Week Low 4.52
Average Volume 114,568
200-Day Moving Average 7.8328
50-Day Moving Average 6.1046
20-Day Moving Average 5.378
10-Day Moving Average 5.403
Average True Range 0.4288
ADX 21.84
+DI 17.1799
-DI 18.583
Chandelier Exit (Long, 3 ATRs ) 4.9936
Chandelier Exit (Short, 3 ATRs ) 5.8064
Upper Bollinger Band 6.0931
Lower Bollinger Band 4.6629
Percent B (%b) 0.5
BandWidth 26.593529
MACD Line -0.1984
MACD Signal Line -0.2658
MACD Histogram 0.0674
Fundamentals Value
Market Cap 23.18 Million
Num Shares 4.31 Million
EPS -14.07
Price-to-Earnings (P/E) Ratio -0.38
Price-to-Sales 35.66
Price-to-Book 0.66
PEG Ratio 0.03
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.06
Resistance 3 (R3) 6.12 5.97 5.94
Resistance 2 (R2) 5.97 5.79 5.93 5.90
Resistance 1 (R1) 5.67 5.69 5.60 5.61 5.87
Pivot Point 5.52 5.52 5.48 5.48 5.52
Support 1 (S1) 5.22 5.34 5.15 5.16 4.89
Support 2 (S2) 5.07 5.24 5.03 4.86
Support 3 (S3) 4.77 5.07 4.82
Support 4 (S4) 4.71